Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related posts2023 Spring NewsletterApril 19, 2023An Unexpected Benefit of Adding the Patient Voice to Medical Education—Train Providers to Be BetterFebruary 26, 2025Subcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL AmyloidosisJuly 2, 2020 Previous postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosisNext post2026 Winter Newsletter
